


Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable NSCLC

- Adjuvant, perioperative and neoadjuvant chemoimmunotherapy regimens are FDA-approved SOC in resectable NSCLC; there are no comparisons between them
- PROSPECT compares adjuvant to perioperative chemoimmunotherapy

Primary Endpoints: 3-year rwEFS & OS

Secondary endpoints: surgical & R0 resection rates; SAE, association between pCR & rwEFS



Key eligibility criteria: Stage IIA to IIIB (cN2a) NSCLC (AJCC9); ECOG 02
Stratification factors: N0/N1 v N2a; - PD-L1 score

PRAGMATIC FEATURES

- Minimal data collection: AEs causing hospitalization, discontinuation or death.
- PS 2 eligible.
- Regimen-agnostic: Based on FDA/NCCN approval.
- Local labs, scans encouraged.
- Regimen selection and dose modifications according to treating physician.
- Response/progression based on local PI; NO use of RECIST

PIs: Daniel Morgensztern, Raid Aljumaili

Co-PIs: Linda Martin, Ray Osarogiagbon

Stats Lead: Sumithra Mandrekar and Yingqi Zhao

Alliance Lung Chair: Thomas Stinchcombe

SWOG Lung Chair: Jhanelle Gray, MD